U.S. And Europe Digital Pathology Market To Reach $994.0 Million By 2030

U.S. And Europe Digital Pathology Market Growth & Trends

The U.S and Europe digital pathology market size is expected to reach USD 994.0 million by 2030, registering a CAGR of 7.2% over the forecast period, according to a new study by Grand View Research, Inc. Digital pathology encompasses the capture, organization, dissemination, and analysis of pathology data and slides within a digital framework.Digital pathology enables high-resolution imaging and advanced visualization tools, allowing pathologists to examine tissue samples in greater detail. This leads to more accurate and precise diagnoses, especially for complex or rare cases. New digital pathology technologies are developing to enhance the communication between the collection of samples and the creation of pathology reports with updated data.

One such technology is Multiplexing. It is a cutting-edge technique for locating or quantifying several proteins in a single material. The discipline of digital pathology is projected to undergo a revolution as a result of the incorporation of cutting-edge multiplexing techniques, such as automated multispectral slide imaging. Some of the other techniques include the use of automated molecular fluorescent tagging and imaging systems, merging qdots with multispectral imaging, etc. The use of these cutting-edge imaging techniques in digital pathology has the potential to raise diagnostic precision, decrease workloads, boost productivity, and more effectively integrate digital pictures into information systems, thereby driving the market. Furthermore, various initiatives are been undertaken to promote and integrate digital pathology into the healthcare systems.

These initiatives are aimed at leveraging technology for improved patient care, research, and education. For instance, in March 2022, the National Pathology Imaging Co-operative (NPIC) created prospects for NHS trusts across the nation to transition to digital pathology, thereby enhancing patient diagnoses. This initiative is fueled by recent funding and the broader implementation of Sectra's digital pathology solution and Vendor Neutral Archive (VNA). Furthermore, prominent players are focusing on various strategies, including partnerships, novel product innovations, research collaborations, and mergers and acquisitions, as avenues to gain a competitive edge. For instance, in July 2020, Paige, a player in computational pathology, obtained clearance from the U.S. FDA (510(k)) for its FullFocus digital pathology image viewer designed for primary diagnoses.

This clearance authorized the in vitro diagnostic (IVD) application of FullFocus, in conjunction with Philips' Ultra-Fast Scanner. In August 2023, Paige entered into a collaborative effort with Ohio State University Wexner Medical Center and its associated community hospitals. This collaboration involves a multi-arm study to assess the clinical utility, health economics, and impact on accuracy, efficiency, and cost savings of utilizing AI tools in diagnosing cancer within a community hospital environment. OSWMC will deploy the Paige Prostate Suite, which includes the FDA-approved AI-powered pathology algorithm known as Paige Prostate Detect. The study aims to evaluate disparities between diagnoses made with and without AI assistance. Such initiatives are expected to fuel the market growth over a forecast period.

 Request a free sample copy or view report summary: U.S. And Europe Digital Pathology Market Report

U.S. And Europe Digital Pathology Market Report Highlights

• In 2022, the device segment accounted for the largest market share of 51.9%.Digital pathology devices offer high-resolution imaging and advanced visualization tools. Also, these devices integrate with electronic health records (EHRs), allowing seamless data exchange and comprehensive patient information, thereby driving the market

• Based on application, the academic research segment accounted for 45.8% of the total share in 2022. Digital pathology provides high-resolution imaging and advanced analysis tools that are particularly valuable for detailed research studies

• Also, it allows easy sharing of images, facilitating collaborative discussions, peer reviews, and interdisciplinary research projects

• The hospitals end-use segment held the largest revenue share of 36.7% in 2022 owing to its rising adoption due to various factors such as improved patient care, streamlined workflows and enhanced diagnostic accuracy

• U.S. accounted for the largest market share of more than 56.3% in 2022. The market is driven by various factors such as the need for improved diagnostic accuracy, the integration of digital solutions with healthcare systems, and advancements in imaging technology

U.S. And Europe Digital Pathology Market Segmentation

Grand View Research has segmented the U.S. and Europe digital pathology market on the basis of product, application, end-use, and region:

U.S. & Europe Digital Pathology Product Outlook (Revenue, USD Million, 2018 - 2030)

• Software

• Device

• Storage System

U.S. & Europe Digital Pathology Application Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Discovery & Development

• Academic Research

• Disease Diagnosis

U.S. & Europe Digital Pathology End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Software

• Biotech & Pharma Companies

• Diagnostic Labs

• Academic & Research Institutes

U.S. & Europe Digital Pathology Regional Outlook (Revenue, USD Million, 2018 - 2030)

• U.S.

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Russia

  • Spain

  • The Netherlands

  • Switzerland

  • Sweden

List of Key Players in the U.S. And Europe Digital Pathology Market

• Leica Biosystems Nussloch GmbH (Danaher)

• Hamamatsu Photonics, Inc.

• Koninklijke Philips N.V.

• Olympus Corporation

• F. Hoffmann-La Roche Ltd.

• Mikroscan Technologies, Inc

• Inspirata, Inc.

• Epredia (3DHISTECH Ltd.)

• Visiopharm A/S

• Huron Technologies International Inc.

• ContextVision AB

• Owkin

• Lunit

• Tempus Labs

• DeepBio